

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr **MINT-TELMISARTAN**

Telmisartan Tablets

Tablets, 40 mg and 80 mg, Oral

USP

Angiotensin II AT1 Receptor Blocker

Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, ON
L5T 2M3

Date of Initial Authorization:
MAR 06, 2019

Date of Revision:
SEP 15, 2023

Submission Control Number: 278358

RECENT MAJOR LABEL CHANGES

2 CONTRAINDICATIONS	09/2023
7 WARNINGS AND PRECAUTIONS	09/2023

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
Pediatrics.....	4
Geriatrics.....	4
2 CONTRAINDICATIONS	4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4 DOSAGE AND ADMINISTRATION	5
Dosing Considerations	5
Recommended Dose and Dosage Adjustment	5
Administration	6
Missed Dose	6
5 OVERDOSAGE	6
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	6
7 WARNINGS AND PRECAUTIONS	6
7.1	9
Special Populations.....	9
7.1.1 Pregnant Women.....	9
7.1.2 Breast-feeding.....	10
7.1.3 Pediatrics.....	10
7.1.4 Geriatrics.....	10
8 ADVERSE REACTIONS	10
8.1 Adverse Reaction Overview	10
8.2 Clinical Trial Adverse Drug Reactions.....	10

8.3	Less Common Clinical Trial Adverse Reactions	14
8.4	15
	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data	15
8.5	Post-Market Adverse Reactions.....	16
9	DRUG INTERACTIONS	16
	Serious Drug Interactions	16
9.4	17
	Drug-Drug Interactions	17
9.5	20
	Drug-Food Interactions.....	20
	Drug-Herb Interactions.....	20
	Drug-Laboratory Test Interactions.....	20
10	CLINICAL PHARMACOLOGY.....	20
10.1	Mechanism of Action	20
10.2	Pharmacodynamics.....	20
10.3	Pharmacokinetics.....	22
11	STORAGE, STABILITY AND DISPOSAL.....	23
12	SPECIAL HANDLING INSTRUCTIONS.....	23
	There are no special handling instructions.	23
	PART II: SCIENTIFIC INFORMATION	24
13	PHARMACEUTICAL INFORMATION	24
14	CLINICAL TRIALS	25
14.1	Clinical Trials by Indication	25
14.2	Comparative Bioavailability Studies	30
15	MICROBIOLOGY	31
16	NON-CLINICAL TOXICOLOGY	31
17	SUPPORTING PRODUCT MONOGRAPHS.....	32
	PATIENT MEDICATION INFORMATION	33

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Treatment of Essential Hypertension

MINT-TELMISARTAN (telmisartan) is indicated for the treatment of mild to moderate essential hypertension in adults.

MINT-TELMISARTAN may be used alone or in combination with thiazide diuretics.

The concurrent use with angiotensin converting enzyme inhibitors is not recommended.

Risk Reduction of Cardiovascular Morbidity

MINT-TELMISARTAN is indicated to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in adults 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme inhibitor (ACEI).

High risk of cardiovascular events includes evidence of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or diabetes mellitus with evidence of end-organ damage. Telmisartan has been used with other required treatment such as other antihypertensives (including ACEI), antiplatelet or statins ([see 7 WARNINGS AND PRECAUTIONS](#), [9 DRUG INTERACTIONS](#) and [14 CLINICAL TRIALS](#) section).

1.1 Pediatrics

Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of telmisartan for in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (> 65 years of age): No dose adjustment is necessary for geriatric patients. It should be recognized, however, that greater sensitivity in some older individuals cannot be ruled out.

2 CONTRAINDICATIONS

MINT-TELMISARTAN (telmisartan) is contraindicated in:

- Concomitant use of angiotensin receptor blockers (ARBs) –including telmisartan with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 ml/min/1.73m²) is contraindicated ([see 7 WARNINGS AND PRECAUTIONS, Cardiovascular, Dual Blockade of the Renin-Angiotensin System \(RAS\) and Renal](#), and [9 DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin System \(RAS\) with ARBs, ACEIs or aliskiren-containing drugs](#)).
- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#) section of the product monograph
- Pregnant women ([see 7.1.1 Pregnant Women](#))
- Breast-feeding ([see 7.1.2 Breast-feeding](#))
- Patients with mannitol intolerance

- Mannitol: MINT-TELMISARTAN tablets contain 341 mg of mannitol per maximum recommended daily dose.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

- **When used in pregnancy, angiotensin receptor (AT1) blockers (ARB) can cause injury or even death of the developing fetus. When pregnancy is detected, MINT-TELMISARTAN should be discontinued as soon as possible (see [7.1 Special Populations](#)).**

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- The antihypertensive effect is present within 2 weeks and maximal reduction is generally attained after four weeks. If additional blood pressure reduction is required, a thiazide diuretic may be added.

4.2 Recommended Dose and Dosage Adjustment

Treatment of Essential Hypertension:

The recommended dose of MINT-TELMISARTAN (telmisartan) is 80 mg once daily.

Patients with renal Impairment

No initial dosing adjustment is necessary for elderly patients or for patients with renal impairment, but greater sensitivity in some older individuals cannot be ruled out. Markedly reduced telmisartan plasma levels were observed in patients on hemodialysis.

Patients with hepatic Impairment

For patients with hepatic impairment a starting dose of 40 mg is recommended and should be administered with caution (see [7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic](#)).

Risk Reduction of Cardiovascular Morbidity:

The recommended dose is 80 mg once daily in patients 55 years or older at high risk for a cardiovascular event. It is not known whether doses lower than 80 mg of telmisartan are effective in preventing cardiovascular morbidity. It can be administered with other antihypertensive agents except an ACEI.

When initiating telmisartan therapy at this dose, monitoring of blood pressure is recommended, and if appropriate adjustment of medications that lower blood pressure may be necessary.

Drug discontinuation

If laryngeal stridor or angioedema of the face, extremities, lips, tongue, or glottis occurs, MINT-TELMISARTAN should be discontinued immediately, the patient treated appropriately in accordance with accepted medical care, and carefully observed until the swelling disappears.

When pregnancy is detected, MINT-TELMISARTAN should be discontinued as soon as possible.

4.4 Administration

MINT-TELMISARTAN tablets are for once-daily oral administration and should be swallowed whole with liquid. MINT-TELMISARTAN can be taken with or without food.

4.5 Missed Dose

MINT-TELMISARTAN (telmisartan) should be taken at the same time each day, preferably in the morning. However, if a dose is missed during the day, the next dose should be continued at the usual time. Do not double dose.

5 OVERDOSAGE

Limited data are available with regard to overdosage in humans. The most prominent manifestations of overdosage were hypotension and/or tachycardia; bradycardia also occurred. If symptomatic hypotension should occur, supportive treatment should be instituted.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
oral	Tablet: 40 mg and 80 mg telmisartan	mannitol, sodium hydroxide, meglumine, povidone, sodium stearyl fumarate, magnesium stearate

MINT-TELMISARTAN (telmisartan) are available as white to off-white, oval shaped, biconvex, uncoated tablets containing 40 mg or 80 mg of telmisartan. Tablets are plain on one side and have been debossed on other side with 'L203' or 'L204' for 40 mg and 80 mg strengths, respectively.

MINT-TELMISARTAN 40 mg tablets are available individually blister sealed in cartons of 100 tablets (10 blister cards of 10 tablets each) or in HDPE bottles of 30 or 100 tablets.

MINT-TELMISARTAN 80 mg tablets are available individually blister sealed in cartons of 100 tablets (10 blister cards of 10 tablets each) or in HDPE bottles of 30 or 100 tablets.

7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#)

General

A case of rare but fatal angioedema occurred in a patient who had been medicated for about 6 months with telmisartan, the active component of MINT-TELMISARTAN. The Autopsy Report described evidence of edema of the laryngeal mucosa, with terminal respiratory and circulatory failure. This is in the context of approximately 5.2 million patient-years exposure to telmisartan annually.

In instances where swelling is confined to the face and lips, the condition generally resolves without treatment, although antihistamines may be useful in relieving symptoms. Where there is involvement of tongue, glottis, or larynx, likely to cause airway obstruction, appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous epinephrine solution 1:1000) should be administered promptly (see [8.5 Post Marketing Adverse Drug Reactions](#)).

Patients with a known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated with MINT-TELMISARTAN (see [8.2 Clinical Trial Adverse Drug Reactions](#) and [8.5 Post Market Adverse Drug Reactions](#)).

Cardiovascular

Aortic and Mitral Valve Stenosis, Obstructive Hypertrophic Cardiomyopathy

As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. These patients are at risk of decreased coronary perfusion resulting from a cardiac output that is limited by a fixed cardiac vascular obstruction.

Volume and/or sodium-depleted patients:

In patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MINT-TELMISARTAN. Such conditions, especially volume and/or sodium depletion, should be corrected prior to administration of MINT-TELMISARTAN. In these patients, because of the potential fall in blood pressure, therapy should be started under close medical supervision.

Ischaemic heart disease

Similar considerations apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident.

Dual blockade of the Renin-Angiotensin System (RAS)

There is evidence that co-administration of angiotensin receptor blockers (ARBs), such as MINT-TELMISARTAN, or of angiotensin-converting-enzyme inhibitors (ACEIs) with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR < 60 ml/min/1.73m²). Therefore, the use of MINT-TELMISARTAN in combination with aliskiren-containing drugs is contraindicated in these patients (see [2 CONTRAINDICATIONS](#)).

Further, co-administration of ARBs, including MINT-TELMISARTAN, with other agents blocking the RAS, such as ACEIs or aliskiren-containing drugs, is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia.

Diabetic Patients:

In diabetic patients with undiagnosed coronary artery disease (CAD) on blood pressure lowering therapy, the risk of fatal myocardial infarction and unexpected cardiovascular death may be increased.

In patients with diabetes mellitus, CAD may be asymptomatic and therefore undiagnosed. These patients should undergo appropriate diagnostic evaluation, e.g. exercise stress testing, to detect and to treat CAD accordingly before initiating blood pressure lowering treatment with MINT-TELMISARTAN.

Driving and Operating Machinery

No studies on the effect on the ability to drive and use machines have been performed. However, when driving vehicles or operating machinery it should be taken into account that dizziness, drowsiness, syncope or vertigo may occasionally occur when taking antihypertensive therapy.

If patients experience these adverse events, they should avoid potentially hazardous tasks such as driving or operating machinery.

Endocrine and Metabolism

Hyperkalemia:

Drugs such as telmisartan that affect the renin-angiotensin-aldosterone system can cause hyperkalemia. Monitoring of serum potassium in patients at risk is recommended. Based on experience with the use of drugs that affect the renin-angiotensin system, concomitant use with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase the potassium level (heparin, etc.) may lead to a greater risk of an increase in serum potassium.

The use of a dual renin-angiotensin-aldosterone system (RAAS) blockade may lead to increased occurrence of hyperkalemia when given as add-on therapy in patients with controlled blood pressure.

Hepatic/Biliary/Pancreatic

Hepatic Impairment: As the majority of telmisartan is eliminated by biliary excretion, patients with cholestasis, biliary obstructive disorders or hepatic insufficiency have reduced clearance of telmisartan. Three to four fold increases in C_{max} and AUC were observed in patients with liver impairment as compared to healthy subjects. Telmisartan should be used with caution in these patients (see [4 DOSAGE AND ADMINISTRATION](#)).

Monitoring and Laboratory Tests

For specific monitoring and laboratory tests, see [7 WARNINGS AND PRECAUTIONS](#) (Cardiovascular, Endocrine and Metabolism, Hepatic and Renal) and [9 DRUG INTERACTIONS](#) sections.

Renal

In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, dual blockade of the renin-angiotensin-aldosterone system (e.g. concomitant use of an ARB with an ACE-inhibitor or the direct renin-inhibitor aliskiren) and treatment with agents that inhibit this system have been associated with oliguria, progressive azotemia, and rarely acute renal failure and/or death. There is no experience with long term use of telmisartan in patients with unilateral or bilateral renal artery stenosis but an effect similar to that seen with ACE inhibitors should be anticipated. In susceptible patients, concomitant diuretic use may further increase the risk. Use of telmisartan should include appropriate assessment of renal function in these types of patients.

There is no experience regarding the administration of MINT-TELMISARTAN in patients with a recent kidney transplant.

Renal Impairment

The use of ARBs – including telmisartan – or of ACEIs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR < 60 ml/min/1.73m²). (See [2 CONTRAINDICATIONS](#) and [9 DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin System \(RAS\) with ARBs, ACEIs, or aliskiren-containing drugs](#)).

Telmisartan is not removed from blood by hemofiltration and is not dialyzable.

Reproductive Health: Female and Male Potential

- Fertility

No studies on fertility in humans have been performed. (see [16 NON-CLINICAL TOXICOLOGY, Reproduction](#)).

7.1 Special Populations

7.1.1 Pregnant Women

Drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) can cause fetal and neonatal morbidity and death when administered to pregnant women.

The use of angiotensin receptor (AT1) blockers (ARBs) is not recommended during pregnancy and should not be initiated during pregnancy. Epidemiological evidence regarding the risk of teratogenicity following exposure to angiotensin converting enzyme inhibitors (another class of therapeutic products interfering with the RAAS) during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with ARB, similar risks may exist for this class of drugs. Patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II blockers should be stopped immediately, and, if appropriate, alternative therapy should be started.

Preclinical studies with telmisartan do not indicate teratogenic effect, but have shown fetotoxicity.

The use of ARBs during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia).

Infants with a history of in utero exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion may be required as a means of reversing hypotension and/or substituting for disordered renal function; however, limited experience with those procedures has not been associated with significant clinical benefit.

It is not known if telmisartan can be removed from the body by hemodialysis.

No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50 mg/kg/day and to pregnant rabbits at oral doses up to 45 mg/kg/day with saline supplementation. In rabbits, fetotoxicity (total resorptions) associated with maternal toxicity (reduced body weight gain, mortality) was observed at the highest dose level (45 mg/kg/day). In rats, maternally toxic (reduction in body weight gain and food consumption) telmisartan doses of 50 mg/kg/day in late gestation and during lactation were observed to produce adverse effects in rat fetuses and neonates, including reduced viability, low birth weight, delayed maturation, and decreased weight gain. Significant levels of telmisartan were present in rat milk and rat fetuses' blood during late gestation.

7.1.2 Breast-feeding

It is not known whether telmisartan is excreted in human milk but significant levels have been found in the milk of lactating rats. Because many drugs are excreted in human milk and because of their potential for affecting the nursing infant adversely, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

7.1.3 Pediatrics

Pediatrics (< 18 years of age): MINT-TELMISARTAN is not recommended for use in children below 18 years due to limited data on safety and efficacy.

7.1.4 Geriatrics

Geriatrics (> 65 years of age): Of the total number of patients receiving telmisartan in clinical studies, 551 (18.6%) were 65 to 74 years of age and 130 (4.4%) were ≥ 75 years. No overall age-related differences were seen in the adverse effect profile, but greater sensitivity in some older patients cannot be ruled out.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

In patients treated for hypertension the overall incidence of adverse events reported with telmisartan (41.4%) was usually comparable to those reported with placebo (43.9%) in controlled clinical trials. The incidence of adverse events was not dose related and showed no correlation with gender, age or race of the patients. The safety profile of telmisartan in patients treated for prevention of cardiovascular morbidity and mortality was consistent with that obtained in hypertensive patients.

8.2 Clinical Trial Adverse Drug Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Telmisartan has been evaluated for safety in 27 clinical trials involving 7968 patients treated for hypertension. Of these 7968 patients, 5788 patients were treated with telmisartan monotherapy including 1058 patients treated for ≥ 1 year and 1395 patients treated in placebo-controlled trials.

In placebo-controlled trials in the registration program for hypertension, discontinuation of therapy due to adverse events was required in 2.8% of telmisartan patients and 6.1% of placebo patients. The following potentially serious adverse events have been reported rarely with telmisartan in controlled clinical trials: syncope and hypotension. In placebo-controlled trials, no serious adverse event was reported with a frequency of greater than 0.1% in telmisartan-treated patients.

The safety profile of telmisartan in patients treated for risk reduction of cardiovascular morbidity was consistent with that obtained in hypertensive patients. In this program, 11% of patients treated with

telmisartan discontinued study medication due to adverse events. The most common adverse events that led to discontinuation were dizziness, hypotension and headache.

The adverse drug reactions listed below have been accumulated from controlled clinical trials in patients treated for hypertension and from post-marketing reports. The listing also takes into account serious adverse events and adverse events leading to discontinuation reported in three clinical long-term studies including 21642 patients treated with telmisartan for prevention of cardiovascular morbidity and mortality for up to six years.

All Clinical Trials

The adverse drug events listed below have been accumulated from 27 clinical trials including 5788 hypertensive patients treated with telmisartan. Adverse events have been ranked under headings of frequency using the following convention: very common ($\geq 1/10$); common ($\geq 1/100, <1/10$); uncommon ($\geq 1/1000, <1/100$); rare ($\geq 1/10000, <1/1000$); very rare ($< 1/10000$)

Body as a Whole, General:

Common: Chest pain, influenza-like symptoms, fatigue, conjunctivitis.

Uncommon: Hyperhidrosis, asthenia (weakness).

Blood and Lymphatic System:

Uncommon: Anaemia.

Rare: Thrombocytopenia.

Not known: Eosinophilia.

Cardiovascular System:

Common: Edema, palpitation.

Uncommon: Bradycardia, orthostatic hypotension, hypotension.

Rare: Tachycardia.

Central and Peripheral Nervous System:

Very Common: Headache.

Common: Dizziness, insomnia.

Uncommon: Vertigo.

Eye Disorders:

Rare: Visual disturbance.

Gastro-Intestinal System:

Common: Abdominal pain, diarrhoea, dyspepsia, nausea, constipation, gastritis.

Uncommon: Dry mouth, flatulence, vomiting.

Rare: Abdominal discomfort.

Hepato-biliary Disorders:

Rare: Hepatic function abnormal/liver disorder*.

*Most cases of hepatic function abnormal / liver disorder from post-marketing experience with telmisartan occurred in patients in Japan, who are more likely to experience these adverse reactions

Immune System:

Rare: Hypersensitivity.

Not known: Anaphylactic reaction, angioedema.

Infections and Infestations:

Uncommon: Upper respiratory tract infections (including pharyngitis, sinusitis, bronchitis, rhinitis and coughing) and urinary tract infections, cystitis.

Not known: Sepsis including fatal outcome.

Investigations:

Uncommon: Blood creatinine increased.

Rare: Blood uric acid increased, hepatic enzyme increased, blood creatinine phosphokinase increased, haemoglobin decreased.

Metabolism and Nutrition Disorders:

Uncommon: Hyperkalemia.

Rare: Hypoglycemia (in diabetic patients).

Musculo-Skeletal System:

Common: Arthralgia, muscle spasms (cramps in legs) or pain in extremity (leg pain), myalgia, arthritis, arthrosis.

Uncommon: Tendon pain (tendonitis like symptoms), back pain.

Nervous System:

Uncommon: Syncope (faint).

Psychiatric System:

Common: Anxiety, nervousness.

Uncommon: Depression.

Renal and Urinary System:

Uncommon: Renal impairment including acute kidney injury.

Respiratory System:

Common: Dyspnea.

Skin and Appendages System:

Common: Skin disorders like rash.

Uncommon: Pruritus.

Rare: Erythema, drug eruption, eczema, toxic skin eruption.

Not known: Urticaria.

Hemoglobin:

Infrequently, a decrease in hemoglobin has been observed which occurs more often during treatment with telmisartan than with placebo.

Placebo-Controlled Trials

In patients treated for hypertension the overall incidence of adverse events reported with telmisartan

(41.4%) was usually comparable to those reported with placebo (43.9%) in controlled clinical trials.

Adverse events occurring in $\geq 1\%$ of 1395 hypertensive patients treated with telmisartan monotherapy in placebo-controlled clinical trials, regardless of drug relationship, include the following:

Table 2 Adverse Events Occurring in > 1% of Hypertensive Patients Treated with Telmisartan Monotherapy

Adverse Event, by System	Telmisartan Total N = 1395 %	Placebo N = 583 %
Body as a Whole		
Back Pain	2.7	0.9
Chest Pain	1.3	1.2
Fatigue	3.2	3.3
Influenza-Like Symptoms	1.7	1.5
Pain	3.5	4.3
Central & Peripheral Nervous System		
Dizziness	3.6	4.6
Headache	8.0	15.6
Somnolence	0.4	1.0
Gastrointestinal System		
Diarrhea	2.6	1.0
Dyspepsia	1.6	1.2
Nausea	1.1	1.4
Vomiting	0.4	1.0
Musculoskeletal System		
Myalgia	1.1	0.7
Respiratory System		
Coughing	1.6	1.7
Pharyngitis	1.1	0.3
Sinusitis	2.2	1.9
Upper Respiratory Tract Infection	6.5	4.6
Heart Rate and Rhythm Disorders		
ECG abnormal specific	0.2	1.0

Adverse Event, by System	Telmisartan Total N = 1395 %	Placebo N = 583 %
Palpitation	0.6	1.0
Cardiovascular Disorders, General		
Hypertension	1.0	1.7
Oedema peripheral	1.0	1.2

The incidence of adverse events was not dose-related and did not correlate with the gender, age, or race of patients.

8.3 Less Common Clinical Trial Adverse Reactions

In addition, the following adverse events, with no established causality, were reported at an incidence <1% in placebo-controlled clinical trials.

Autonomic Nervous System Disorders: sweating increased.

Body as a Whole: abdomen enlarged, allergy, cyst nos, fall, fever, leg pain, rigors, syncope.

Cardiovascular Disorders, General: hypotension, hypotension-postural, leg edema.

Central & Peripheral Nervous System Disorder: hypertonia, migraine-aggravated, muscle contraction-involuntary.

Gastrointestinal System Disorders: anorexia, appetite increased, flatulence, gastrointestinal disorder nos, gastroenteritis, gastroesophageal reflux, melena, mouth dry, abdominal pain.

Heart Rate & Rhythm Disorders: arrhythmia, tachycardia.

Metabolic & Nutritional Disorders: diabetes mellitus, hypokalaemia.

Musculoskeletal System Disorders: arthritis, arthritis aggravated, arthrosis, bursitis, fascitis plantar, tendinitis.

Myo Endo Pericardial & Valve Disorders: myocardial infarction.

Psychiatric Disorders: nervousness.

Red Blood Cell Disorders: anemia.

Reproductive Disorders, Female: vaginitis.

Resistance Mechanism Disorders: abscess, infection, bacterial, moniliasis genital, otitis media.

Respiratory System Disorders: bronchospasm, epistaxis, pneumonia, bronchitis.

Skin & Appendage Disorders: rash, skin dry.

Urinary System Disorders: Dysuria, hematuria, micturition disorder, urinary tract infection.

Vascular (Extracardiac) Disorders: cerebrovascular disorder, purpura.

Vision Disorders: vision abnormal.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

In placebo-controlled clinical trials involving 1041 patients treated with telmisartan monotherapy, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of telmisartan.

Creatinine, Blood Urea Nitrogen:

Increases in BUN (≥ 11.2 mg/dl) and creatinine (≥ 0.5 mg/dl) were observed in 1.5% and 0.6% of telmisartan-treated patients; the corresponding incidence was 0.3% each for placebo-treated patients. These increases occurred primarily with telmisartan in combination with hydrochlorothiazide. One telmisartan treated patient discontinued therapy due to increases in creatinine and blood urea nitrogen.

Hemoglobin, Hemotocrit:

Clinically significant changes in hemoglobin and hematocrit (< 10 g/dl and $< 30\%$, respectively) were rarely observed with telmisartan treatment and did not differ from rates in placebo-treated patients. No patients discontinued therapy due to anemia.

Serum Uric Acid:

An increase in serum uric acid (> 2.7 mg/dl) was reported in 1.7% of patients treated with telmisartan and in 0.0% of patients treated with placebo. Clinically significant hyperuricemia (> 10 mEq/L) was observed in 2.3% of patients with telmisartan, with 0.4% reported in patients at baseline. Increases in serum uric acid were primarily observed in patients who received telmisartan in combination with hydrochlorothiazide. No patient was discontinued from treatment due to hyperuricemia.

Liver Function Tests:

Clinically significant elevations in AST and ALT (> 3 times the upper limit of normal) occurred in 0.1% and 0.5%, respectively of patients treated with telmisartan compared to 0.8% and 1.7% of patients receiving placebo. No telmisartan-treated patients discontinued therapy due to abnormal hepatic function.

Serum Potassium:

Marked laboratory changes in serum potassium ($\geq \pm 1.4$ mEq/L) occurred rarely and with a lower frequency in telmisartan-treated patients (0.3%, 0.1%, respectively) than in placebo patients (0.6%,

0.3%, respectively). Clinically significant changes in potassium (that exceeded 3mEq/L) were found in 0.6% of telmisartan-treated patients, with 0.5% of these reported at baseline. The corresponding rates for placebo-treated patients were 0.6% and 0.8%.

Cholesterol:

In placebo-controlled trials, marked increases in serum cholesterol were reported in a total of 6 telmisartan-treated patients (0.4%) and no placebo patients. Two of these patients were followed over time, in both cases cholesterol values reverted to baseline levels.

Serum elevations in cholesterol were reported as adverse events in 11 of 3445 patients (0.3%) in all clinical trials. There were no reported cases of hypercholesterolemia in telmisartan-treated patients in placebo-controlled trials.

8.5 Post-Market Adverse Reactions

Since the introduction of telmisartan in the market, cases of anxiety, dizziness, vision troubled, vertigo, abdominal distension, abdominal pain, retching, hyperhidrosis, arthralgia, myalgia, muscle spasm, back pain, asthenia, pain in extremity, fatigue, chest pain, blood creatinine increased, erythema, pruritus, syncope/faint, insomnia, depression, stomach discomfort, vomiting, hypotension (including orthostatic hypotension), bradycardia, tachycardia, abnormal hepatic function/liver disorder, renal impairment (including acute kidney injury), hyperkalemia, dyspnoea, anaemia, eosinophilia, thrombocytopenia, hyponatraemia and weakness have been reported. The frequency of these effects is unknown. As with other angiotensin II blockers, rare cases of angioedema (including fatal outcome), pruritus, rash and urticaria have been reported.

Cases of muscle pain, muscle weakness, myositis and rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers.

In addition, since the introduction of telmisartan in the market, cases with increased blood creatinine phosphokinase (CPK) have been reported.

9 DRUG INTERACTIONS

Serious Drug Interactions

Serious Drug Interactions

Concomitant use of angiotensin receptor antagonists (ARBs) –including telmisartan – with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 ml/min/1.73m²) is contraindicated (see [7 WARNINGS AND PRECAUTIONS, Cardiovascular, Dual blockade of the Renin-Angiotensin System \(RAS\)](#) and [Renal](#), and [9.4 Drug-Drug Interactions, Dual Blockade of the Renin-Angiotensin System \(RAS\) with ARBs, ACEIs or aliskiren-containing drugs](#)).

9.4 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Coadministration of telmisartan also did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, or hydrochlorothiazide

Table 3: Established or Potential Drug-Drug Interactions with telmisartan

Telmisartan	Effect	Clinical comment
Agents increasing serum potassium	Telmisartan component of telmisartan tablets reduces the production of aldosterone.	Potassium-sparing diuretics or potassium supplements should be given only for documented hypokalemia and with frequent monitoring of serum potassium. Potassium-containing salt substitutes should also be used with caution. Concomitant thiazide diuretic use may attenuate any effect that telmisartan may have on serum potassium.
Digoxin	When telmisartan was co-administered with digoxin, mean increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed.	It is recommended that digoxin levels be monitored with appropriate dose adjustments when initiating, adjusting or discontinuing MINT-TELMISARTAN, to maintain appropriate plasma digoxin concentrations.
Diuretics	Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with telmisartan.	The possibility of symptomatic hypotension with the use of telmisartan can be minimized by discontinuing the diuretic prior to initiation of treatment and/or lowering the initial dose of telmisartan (see 7 WARNINGS AND PRECAUTIONS – <u>Cardiovascular</u> , Hypotension and 4 DOSAGE AND ADMINISTRATION). No drug interaction of clinical significance has been identified with thiazide diuretics.

<p>Dual Blockade of the Renin-Angiotensin System (RAS) with ARBs, ACEIs or aliskiren containing drugs</p>	<p>The treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia</p>	<p>Dual Blockade of the renin-angiotensin system with ARBs, ACEIs or aliskiren-containing drugs is contraindicated in patients with diabetes and/or renal impairment, and is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia. (See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin System).</p>
<p>Lithium salts</p>	<p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Rare cases have also been reported with angiotensin II receptor blockers including telmisartan.</p>	<p>Serum lithium level monitoring is advisable during concomitant use.</p>

<p>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</p>	<p>Combinations of angiotensin- II blockers (telmisartan) and NSAIDs (including ASA and COX-2 inhibitors) might have an increased risk for acute renal failure and hyperkalemia.</p> <p>NSAIDs (including ASA and COX-2 inhibitors) and angiotensin-II receptor blockers exert a synergistic effect on the decrease of glomerular filtration. In patients with pre-existing renal impairment, this may lead to acute renal failure.</p>	<p>Blood pressure and kidney function should be monitored more closely in this situation, as occasionally there can be a substantial increase in blood pressure.</p> <p>Monitoring of renal function at the beginning and during the course of the treatment should be recommended.</p> <p>Co-administration of telmisartan did not result in a clinically significant interaction with ibuprofen.</p>
<p>Ramipril</p>	<p>In one study, the co- administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUC₀₋₂₄ and C_{max} of ramipril and ramiprilat.</p>	<p>The clinical relevance of this observation is not known.</p>
<p>Warfarin</p>	<p>Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration;</p>	<p>The decrease in the mean warfarin trough plasma concentration did not result in a change in the International Normalized Ratio (INR).</p>

9.5 Drug-Food Interactions

When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC) of telmisartan varies from approximately 6% (40 mg) to approximately 19% (160 mg), and the reduction in C_{max} varies from approximately 26% (40 mg) to 56% (160 mg). However, three hours after administration, plasma concentrations are similar whether telmisartan is taken with or without food.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Telmisartan is an orally active angiotensin II AT₁ receptor blocker. By selectively blocking the binding of angiotensin II to the AT₁ receptors telmisartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II. Telmisartan does not exhibit any partial agonist activity at the AT₁ receptors, and has essentially no affinity for the AT₂ receptors. AT₂ receptors have been found in many tissues, but to date they have not been associated with cardiovascular homeostasis. In vitro binding studies indicate that telmisartan has no relevant affinity for other receptors nor does it inhibit human plasma renin.

Telmisartan does not inhibit angiotensin converting enzyme, also known as kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin, nor does it affect renin or other hormone receptors or ion channels involved in cardiovascular regulation of blood pressure and sodium homeostasis.

In hypertensive patients blockade of angiotensin II AT₁ receptors results in two to three fold increase in plasma renin and angiotensin II plasma concentrations. Long term effects of increased AT₂ receptor stimulation by angiotensin II are unknown.

10.2 Pharmacodynamics

Treatment of Essential Hypertension

In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak with approximately 40% inhibition persisting for 24 hours.

In hypertensive patients with normal renal function, no clinically significant effects on renal plasma flow, filtration fraction, or glomerular filtration rate were observed. In multiple dose studies in hypertensive patients, telmisartan had no adverse effect on renal function as measured by serum creatinine or blood urea nitrogen.

The antihypertensive effects of telmisartan were demonstrated in 6 placebo-controlled clinical trials, in a total of 1773 patients, 1031 of whom were treated with telmisartan. Upon initiation of antihypertensive treatment with telmisartan, blood pressure was reduced after the first dose and there was a gradual increase in the antihypertensive effect during continued treatment for ≤12 weeks, with

most of the increase occurring during the first month. Onset of antihypertensive activity occurs within 3 hours after administration of a single oral dose. The antihypertensive effect of once daily administration of telmisartan is maintained for the full 24-hour dose interval. The magnitude of blood pressure reduction from baseline, after placebo subtraction, was on average (SBP/DBP) -11.3/-7.3 mmHg for telmisartan 40 mg once daily, and -13.7/-8.1 mmHg for telmisartan 80 mg once daily. Upon abrupt cessation of treatment with telmisartan, blood pressure gradually returned to baseline values over a period of several days.

During long term studies (without placebo control) the effect of telmisartan appeared to be maintained for ≥ 1 year.

For those patients treated with telmisartan 80 mg once daily who required additional blood pressure reduction, addition of a low dose of hydrochlorothiazide (12.5 mg) resulted in incremental blood pressure reductions of -9.4/-7.0 mmHg.

The antihypertensive effect of once-daily telmisartan (40-80 mg) was similar to that of once-daily amlodipine (5-10 mg), atenolol (50-100 mg), enalapril (5-20 mg) and lisinopril (10-40 mg).

There was essentially no change in heart rate in telmisartan-treated patients in controlled trials.

In clinical trials with post-dose in-clinic monitoring no excessive blood pressure lowering peak effect was observed even after the first dose, and the incidence of symptomatic orthostasis was very low (0.04%). With automated ambulatory blood pressure monitoring, the 24-hour trough-to-peak ratio for telmisartan was determined to be at least 80% for both systolic and diastolic blood pressure.

The antihypertensive effect of telmisartan is not influenced by patient age, weight or body mass index.

Diabetic Patients: Multiple exploratory post hoc analyses were carried out on the three cardiovascular (CV) outcome trials (ONTARGET, TRANSCEND and PRoFESS). In TRANSCEND and PRoFESS, an increased risk of unexpected CV death was seen with telmisartan versus placebo in diabetics without previously diagnosed coronary artery disease (CAD) but not in those with a documented history of CAD. No such increased risk was demonstrated in ONTARGET for telmisartan versus ramipril in diabetes patients without previously diagnosed CAD.

These findings in diabetics with added cardiovascular risk, could be related to a pre-existing but asymptomatic or silent CAD. Diabetics with undiagnosed and therefore untreated CAD may be at increased risk when lowering blood pressure too far, e.g. when initiating antihypertensive therapy, due to a further reduction of perfusion in an already narrowed coronary artery.

In in vitro studies, telmisartan displaced 125 I-angiotensin II from its binding site at the AT1 receptor with an inhibitor constant (K_i) of 3.7 nM.

In isolated strips of rabbit aorta, telmisartan exerted potent angiotensin II antagonism: the calculated dissociation constant was $K_B 3.3 \cdot 10^{-10}$ M.

In vivo results showed that telmisartan was a potent and long acting blocker antagonist of the functional response to exogenously administered angiotensin II in rats, rabbits and dogs after both intravenous and oral administration. Telmisartan showed dose dependent and long lasting (>24h) antihypertensive effects after single or repeated oral administration in various rodent models of experimental hypertension.

Risk Reduction of Cardiovascular Morbidity

See [14 CLINICAL TRIALS](#) section.

10.3 Pharmacokinetics

Table 4 - Summary of telmisartan pharmacokinetic parameters (arithmetic means, CV%) in healthy volunteers, male, range: 20-47 years

Administration	C _{max} (ng/mL)	T _{max} * (h)	t _½ (h)	AUC _{0-∞} (ng h/mL)	CL (mL/min)	V _z /f (L)
40 mg, single dose, tablet	32.1 (44.9)	1.75 (27.9)	19.6 (36.8)	360 (61.5)	2670 (61.4)	4490 (84.9)

Table 5: Summary of telmisartan pharmacokinetic parameters (geometric means, CV%) in healthy volunteers, males and females, range: 18-45 years

Administration	C _{max} (ng/mL)	T _{max} * (h)	t _½ (h)	AUC _{0-∞} (ng h/mL)	CL (mL/min)	V _z /f (L)
80 mg, single dose, tablet	245 (69.4)	1.00 (0.5-2.00)	27.29 (37.28)	1280 (91.71)	1766 (68.68)	3890 (95.49)

* Median

Absorption: Following oral administration, telmisartan is well absorbed, with a mean absolute bioavailability of about 50%. Mean peak concentrations of telmisartan are reached in 0.5-1 hour after dosing.

The pharmacokinetic profile is characterized by greater than proportional increases of plasma concentrations (C_{max} and AUC) with increasing doses >40 mg. Telmisartan shows bi-exponential decay kinetics with a terminal elimination half life of approximately 24 hours, and does not accumulate in plasma upon repeated once-daily dosing.

Distribution: Telmisartan is >99.5% bound to plasma protein, mainly albumin and α₁-acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with therapeutic doses. The volume of distribution for telmisartan is approximately 500 liters, indicating additional tissue binding sites.

When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC) of telmisartan varies from approximately 6% (40 mg) to approximately 19% (160 mg), and the reduction in C_{max} varies from approximately 26% (40 mg) to 56% (160 mg). However, three hours after administration, plasma concentrations are similar whether telmisartan is taken with or without food.

Metabolism: Telmisartan is metabolized by conjugation with glucuronic acid to form an acylglucuronide of telmisartan. This glucuronide is the only metabolite which has been identified in human plasma and urine. Following both oral dosing and intravenous administration of radiolabeled telmisartan, the parent compound represented approximately 85% and the glucuronide approximately 11% of total radioactivity in plasma. No pharmacological activity has been shown for the glucuronide conjugate.

The CYP 450 isoenzymes are not responsible for telmisartan metabolism.

Elimination: Total plasma clearance of telmisartan is > 800 mL/min. Half-life and total clearance appear to be independent of dose. Biliary excretion is the main route of elimination of telmisartan and its metabolite. Following intravenous and oral administration of C¹⁴ labelled telmisartan 0.91% and 0.49% of administered dose were found in the urine as glucuronide, respectively. Most of the oral and intravenous dose, >97%, was excreted in feces as the parent compound.

Special Populations and Conditions

- **Pediatrics:** Telmisartan pharmacokinetics have not been investigated in patients <18 years of age.
- **Geriatrics:** The pharmacokinetics of telmisartan do not differ between the geriatric and those younger than 65 years. (see [4 DOSAGE AND ADMINISTRATION](#))
- **Sex:** Plasma concentrations of telmisartan are generally 2-3 fold higher in females than in males. No dosage adjustment is necessary. Women have a lower telmisartan clearance and have a greater systolic blood pressure response at trough than men.
- **Genetic Polymorphism:** No studies were conducted to evaluate the influence of genetic polymorphisms on the pharmacokinetics or pharmacodynamics of telmisartan.
- **Ethnic Origin:** Blood pressure in hypertensive black patients (usually a low renin population) is significantly reduced by telmisartan (compared to placebo), but less so than in non-black patients.
- **Hepatic Insufficiency** In patients with hepatic insufficiency, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100%. A lower starting dose should be considered. (see [7 WARNINGS AND PRECAUTIONS](#), and [4 DOSAGE AND ADMINISTRATION](#)).
- **Renal Insufficiency** Renal excretion of telmisartan is negligible. No dosage adjustment is necessary in patients with renal insufficiency. In patients on hemodialysis both C_{max} and AUC of telmisartan were markedly reduced as compared to healthy volunteers. Telmisartan is not removed by hemodialysis. (see [7 WARNINGS AND PRECAUTIONS](#), and [4 DOSAGE AND ADMINISTRATION](#))

11 STORAGE, STABILITY AND DISPOSAL

MINT-TELMISARTAN tablets are hygroscopic and require protection from moisture. Tablets are packaged in bottle and blisters and should be stored at room temperature, 15-30°C (59-86°F). Due to the hygroscopic property of the tablets, they should not be removed from blisters or bottles until immediately prior to administration.

12 SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: Telmisartan

Chemical name: [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'-propyl[2,6'- bi-1H-benzimidazol]-1'-yl)methyl]--(CAS)¹.

Molecular formula and molecular mass: C₃₃H₃₀N₄O₂, 514.62 g/mol

Structural formula:



Physicochemical properties:

Description: Telmisartan is a white to slight yellowish solid.

Solubility: It is sparingly soluble in methylene chloride, slightly soluble in methanol and practically insoluble in water. It dissolves in 1M sodium hydroxide.

Melting Range: 261 – 263°C

Polymorphism: Exhibits two different polymorphic modifications, Form A (thermodynamically more stable) and Form B, and a third pseudo polymorphic form.

Melting Point: 269 ± 1°C (polymorphic Form A)

183 ± 1°C (polymorphic Form B).

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Indication 1

Treatment of mild to moderate essential hypertension in adults

Table 6 : Summary of patient demographics for clinical trials in in the treatment of mild to moderate essential hypertension in adults

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
502.202	Randomized, Double blind, Placebo-controlled in mild to moderate essential hypertensive patients	Treatment doses: 40 mg, 80 mg, 120 mg (40 mg + 80 mg) once daily Route of Administration: Oral Duration of treatment: 4 weeks	207	51.8* (30-68)	62% male/ 38% female
502.203	Randomized, Double blind, Placebo-controlled in mild to moderate essential hypertensive patients	Treatment doses: 20 mg, 40 mg, 80 mg, 120 mg (40 mg + 80 mg), 160 mg (80 mg + 80 mg) once daily Route of Administration: Oral Duration of treatment: 4 weeks	274	52.3* (28-72)	69% male/ 31% female

502.206	Randomized, Double blind, Placebo-controlled in mild to moderate essential hypertensive patients	Treatment doses: 40 mg, 80 mg, 120 mg, 160 mg (80 mg + 80 mg) once daily Route of Administration: Oral Duration of treatment: 12 weeks	440	54.1* (21-83)	64% male/ 36% female
---------	--	--	-----	---------------	-------------------------

* median age

T = telmisartan

Study Results

Table 7: Results of study #502.202 in the treatment of mild to moderate essential hypertension in adults

Primary Endpoints	Associated value and statistical significance for Drug and placebo at specific dosages			
Change from baseline in supine DBP at trough (24 hours post dosing) at last double-blind visit.	<u>Intent-to-Treat Supine Blood Pressure Results</u>			
	<u>Adjusted Mean Changes from Baseline (mmHg)</u>			
	<u>Treatment</u>	<u>N</u>	<u>Systolic</u>	<u>Diastolic</u>
	Placebo	43	+3.5	-1.5
	Telmisartan 40 mg	40	-10.0****	-7.9***
	Telmisartan 80 mg	41	-15.5****	-8.7***
	Telmisartan 120 mg	41	-12.5****	-9.8****
	***: p < 0.001 vs. Placebo			
	****: p < 0.0001 vs. Placebo			

BP = blood pressure

DBP = diastolic blood pressure

SBP = systolic blood pressure

Table 8: Results of study #502.203 in the treatment of mild to moderate essential hypertension in adults

Primary Endpoints	Associated value and statistical significance for Drug and placebo at
-------------------	---

	specific dosages			
Change from baseline in supine DBP at trough (24- hours post-dosing) at the last observation during the double-blind phase	<u>Intent-to-Treat Analysis of the Change from Baseline in Supine Blood Pressure</u>			
		Adjusted ¹ Mean Change (S.E.) (mmHg)		
	<u>Treatment</u>	<u>N</u>	<u>Diastolic</u> (baseline = 102.4)	<u>Systolic</u> (baseline = 151.2)
	Placebo	46	-0.4 (1.2)	3.2 (1.9)
	Telmisartan 20 mg	47	-6.9 (1.1)****	-3.3 (1.8)*
	Telmisartan 40 mg	47	-8.6 (1.2)****	-7.8 (1.9)****
	Telmisartan 80 mg	44	-10.5 (1.2)****	-9.8 (1.9)****
	Telmisartan 120 mg	45	-8.9 (1.2)****	-9.1 (1.9)****
	Telmisartan 160 mg	44	-9.4 (1.2)****	-11.7 (2.0)****
	¹ Based on a model with the effects of baseline blood pressure, center, treatment and treatment- by-center interaction. Legend for treatment comparison with placebo: *: p < 0.05 (two-sided test) ****: p < 0.0001			

BP = blood pressure

DBP = diastolic blood pressure

SBP = systolic blood pressure

Table 9: Results of study #502.206 in the treatment of mild to moderate essential hypertension in adults

Primary Endpoints	Associated value and statistical significance for Drug and placebo at specific dosages			
Change from baseline in supine DBP and SBP at trough (24 hours post- dosing) at the last observation during the double-blind phase.	<u>Intent-to-Treat Analysis of the Change from Baseline in Supine Blood Pressure at Trough</u>			
		Adjusted ¹ Mean Changes (S.E.) (mmHg)		
	<u>Treatment</u>	<u>N</u>	<u>Diastolic</u> (baseline = 100.4)	<u>Systolic</u> (baseline = 153.9)
	Placebo	74	-1.8 (0.9)	+0.8 (1.6)
	Telmisartan 40 mg	72	-9.3 (0.9)****	-11.6 (1.6)****
	Telmisartan 80 mg	71	-9.7 (0.9)****	-11.8 (1.6)****

Primary Endpoints	Associated value and statistical significance for Drug and placebo at specific dosages			
	Telmisartan 120 mg	72	-8.8 (0.9)****	-10.0 (1.5)****
	Telmisartan 160 mg	73	-8.6 (0.9)****	-11.9 (1.5)****
¹ Based on a model with the effects of baseline blood pressure, center, treatment and treatment-by- center interaction ****: p < 0.0001 Note: Significance of the treatment-by-center interaction was 0.5789 and 0.1557 for diastolic and systolic, respectively.				

BP = blood pressure

DBP = diastolic blood pressure

SBP = systolic blood pressure

Indication 2

Reduction of the risk of non-fatal stroke or non-fatal myocardial infarction in adults patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme inhibitor (ACEI).

Table 10: Summary of patient demographics for clinical outcome trial TRANSCEND in the treatment of cardiovascular prevention in patients intolerant of ACEI

502.373	TRANSCEND: Randomized, Double blind, Placebo controlled in ≥ 55 year old patients at high risk for cardiovascular events and intolerant to ACEI	Treatment doses: telmisartan 80 mg and placebo once daily Route of Administration: Oral Duration of treatment: 4.75 years	5,926	66.9	57% male 43% female
---------	--	--	-------	------	------------------------

Table 11: Summary of results of study #502.373 in the treatment of cardiovascular prevention in patients intolerant of ACEI

Primary Endpoints	Associated value and statistical significance for Drug and placebo at specific dosages
Primary: Composite of cardiovascular death, myocardial infarction,	No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart

Primary Endpoints	Associated value and statistical significance for Drug and placebo at specific dosages
stroke or hospitalization for congestive heart failure Secondary: First three components of primary endpoint	failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)]. There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)]. There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).

BP = blood pressure;

DBP = diastolic blood pressure

SBP = systolic blood pressure

TRANSCEND Study #502.373

TRANSCEND randomized in a double-blind fashion 5,926 patients to telmisartan 80 mg once daily or placebo after a 3-4-week run-in period on placebo and then telmisartan [9]. Patients were ≥ 55 years, and at high risk of a CV event as indicated by coronary artery (prior MI, stable or unstable angina, prior PTCA or CABG) or peripheral arterial disease (prior limb bypass or angioplasty, claudication, artery stenosis), prior stroke or TIA or high risk diabetics. All patients had a *known intolerance to ACE inhibitors*. The patient population studied was 57% male, 62% Caucasian, 60% were ≥ 65 years and were followed-up for a median period of 56 months. Patients also received acetylsalicylic acid (75%), statins (56%), beta-blockers (59%), calcium-channel blockers (41%), nitrates (34%) and diuretics (33%). Approximately 83% and 76% of the patients were considered as adherent to the medication at 2 and 4 years, respectively. The *primary endpoint* was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for congestive heart failure. The *secondary endpoint* was a composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

The results summarized in Table 12 indicate that telmisartan may reduce the risk of non-fatal MI or non-fatal stroke but not of total or cardiovascular mortality and may be considered in patients who cannot tolerate an ACE inhibitor.

Table 12: Primary and secondary composite endpoints and components of these endpoints for the full-analysis-set (intent-to-treat) TRANSCEND Study #502.373. Outcomes are for the first event.

OUTCOME	Telmisartan N = 2954 No. of events (%)	Placebo N = 2972 No. of events (%)	Hazard Ratio (95% CI)	p-value
Primary endpoint*	465 (15.7%)	504 (17.0%)	0.92 (0.81, 1.05)	0.216
Secondary endpoint**	384 (13.0%)	440 (14.8%)	0.87 (0.76, 1.00)	0.048
Individual components of the primary/secondary endpoint***				

OUTCOME	Telmisartan N = 2954 No. of events (%)	Placebo N = 2972 No. of events (%)	Hazard Ratio (95% CI)	p-value
Cardiovascular mortality	227 (7.7%)	223 (7.5%)	1.03 (0.85, 1.24)	0.776
Non-fatal MI	114 (3.9%)	145 (4.9 %)	0.79 (0.62, 1.01)	0.057
Non-fatal stroke	112 (3.8%)	136 (4.6%)	0.83 (0.64, 1.06)	0.137
Hospitalization for CHF	134 (4.5%)	129 (4.3%)	1.05 (0.82, 1.34)	0.694
Total mortality	364 (12.3%)	349 (11.7%)	1.05 (0.91, 1.22)	0.491

*Composite of CV death, myocardial infarction, stroke, or hospitalization for heart failure

**Composite of CV death, myocardial infarction, or stroke

*** For individual components of the composite endpoints, all events, regardless whether or not they were the first event, were considered. Therefore, they are more than first events considered for the primary or secondary composite endpoint

14.2 Comparative Bioavailability Studies

A randomized, two-way, single dose, crossover comparative bioavailability study of MINT-TELMISARTAN tablets 80 mg (Mint Pharmaceuticals Inc.) with MICARDIS® 80 mg tablets [Boehringer Ingelheim (Canada) Ltd.] was conducted in healthy, adult, Asian male subjects under fasting conditions. Comparative bioavailability data from 48 subjects that were included in the statistical analysis are presented in the following table:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Telmisartan (1 x 80 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90% Confidence Interval
AUC ₀₋₇₂ (ng·h/mL)	1632.17 2189.67 (74.09)	1555.80 2180.41 (77.65)	104.9	98.6 – 111.7
AUC _I (ng·h/mL)	1877.64 2489.80 (72.70)	1853.55 2484.42 (74.35)	101.8	96.9 – 107.1
C _{max} (ng/mL)	238.70 320.40 (79.63)	233.95 326.19 (82.87)	102.0	89.7 – 116.0

Telmisartan (1 x 80 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90% Confidence Interval
T _{max} ³ (h)	1.13 (0.50 – 6.00)	1.00 (0.33 – 4.00)		
T _½ ⁴ (h)	18.54 (38.12)	18.28 (45.87)		

¹ MINT-TELMISARTAN Tablets 80 mg (Mint Pharmaceuticals Inc.)

² MICARDIS® (telmisartan) 80 mg tablets manufactured by Boehringer Ingelheim (Canada) Ltd., were purchased in Canada.

³ Expressed as the median (range) only.

⁴ Expressed as the arithmetic mean (CV%) only.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

In acute oral toxicity studies no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest oral dose tested. The i.v. LD₅₀ in rats was 150-200 mg/kg in males and 200-250 mg/kg in females.

Chronic oral toxicity of telmisartan was evaluated in studies following administration of doses ≤500 mg/kg for ≤26 weeks in rats, and ≤1 year in dogs. Chronic intravenous toxicity was evaluated in studies of ≤4 weeks at doses ≤20 mg/kg in rats and ≤50 mg/kg in dogs.

Repeated dose administration of telmisartan resulted in marked and long lasting hypotension, hyperplasia of juxtaglomerular apparatus and lesions of the gastrointestinal tract. Further effects were reduced body weight gain, heart weight and red blood cell indices, increased potassium and AST and ALT, the latter in the absence of morphological evidence of toxicity. No effect doses were not identified for decreased erythroid indices, increased BUN and juxtaglomerular hypertrophy/hyperplasia in rats and dogs.

Gastric and/or duodenal mucosal erosions and ulcers were seen in rats given ≥4 mg/kg orally or ≥2 mg/kg i.v. and in dogs given ≥40 mg/kg orally. Most lesions were small, focal or multifocal in distribution and limited to the mucosa and submucosa. Ulcers and erosions healed rapidly after drug withdrawal.

Hypertrophy of the juxtaglomerular apparatus and increased granularity of renin-producing cells of the juxtaglomerular apparatus, afferent arterioles and interlobular arteries of the kidney were observed in

rats at doses of ≥ 1 mg/kg and in dogs at ≥ 5 mg/kg. In rats and dogs subjected to long term treatment with telmisartan, plasma renin activity returned to normal levels after 26 to 52 weeks of treatment. Reversible slight to mild increases in serum potassium levels occurred in rats at oral doses of ≥ 4 mg/kg. In dogs, non-progressive increases in serum potassium levels were noted at 50 and 500 mg/kg in the 52 week oral study. Minimal to mild, reversible increases in blood urea nitrogen and creatinine were evident at oral doses of ≥ 4 mg/kg in rats and ≥ 5 mg/kg in dogs.

Slight to mild reversible reductions of red blood cell count, hematocrit, and/or hemoglobin were observed after repeated oral dosing with telmisartan ≥ 50 mg/kg in the rat and ≥ 5 mg/kg in the dog.

Carcinogenicity:

The carcinogenic potential of telmisartan was assessed in 2-year feeding studies in mice at doses of 10, 100 and 1000 mg/kg and in rats at 3, 15 and 100 mg/kg. Drug administration did not affect survival time in either study and also tumor mortality was not increased. Incidence and time to appearance of palpable masses showed no treatment influence in mice and rats. No increases were observed in overall tumor incidence, incidence of benign and malignant tumors or tumor multiplicity.

Genotoxicity:

Telmisartan was not mutagenic at a concentration range of 10 to 2500 ug/plate in the bacterial reverse mutation assay, with or without metabolic activation. No potential for chromosomal damage was found in the mouse micronucleus test at a dose range of 250 to 1000 mg/kg. No forward mutations at the HPRT locus in V79 cells were induced at a concentration range of 10 to 100 ug/ml, with or without metabolic activation. No chromosomal aberrations were induced in human peripheral lymphocytes *in vitro* at concentrations ≤ 100 ug/ml without metabolic activation and concentrations ≤ 200 ug/ml with metabolic activation.

Reproductive and Developmental Toxicology:

Reproduction

In studies on fertility and reproductive performance in male and female rats no effect on mating performance, reproductive organs, or fertility in either sex, or on litter parameters was observed with telmisartan doses of 5-100 mg/kg. No teratogenic or embryotoxic potential in rats was observed at doses ≤ 50 mg/kg administered from day 7 through day 16 of pregnancy. However, at toxic dose levels, non-clinical studies indicated some hazardous potential of telmisartan to fetal development (increased number of late resorptions in rabbits) and to the postnatal development of the offspring: lower body weight, delayed eye opening, and higher mortality.

No effects of telmisartan on male or female fertility were observed.

Telmisartan was detectable in the placenta, fetus and amniotic fluid of rats after single oral doses of 1 mg/kg.

17 SUPPORTING PRODUCT MONOGRAPHS

1. PrMICARDIS® (telmisartan tablets, 40 mg and 80 mg), submission control 264047, Product Monograph, Boehringer Ingelheim (Canada) Ltd. October 4, 2022.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **MINT-TELMISARTAN**

Telmisartan Tablets, USP

40 mg and 80 mg

Read this carefully before you start taking **MINT-TELMISARTAN** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **MINT-TELMISARTAN**.

Serious Warnings and Precautions

- **MINT-TELMISARTAN should not be used during pregnancy. If you discover that you are pregnant while taking MINT-TELMISARTAN, stop the medication and please contact your healthcare professional as soon as possible.**

What is MINT-TELMISARTAN used for?

- To treat high blood pressure in adults
- To reduce the risk of non-fatal heart attack or non-fatal stroke in adults

How does MINT-TELMISARTAN work?

MINT-TELMISARTAN is an angiotensin receptor blocker (ARB). You can recognize an ARB because its medicinal ingredient ends in “-SARTAN”.

This medicine does not cure your disease. It helps to control it. Therefore, it is important to continue taking MINT-TELMISARTAN regularly even if you feel fine. Do not stop taking your medicine without talking to your healthcare professional.

What are the ingredients in MINT-TELMISARTAN?

Medicinal ingredients: Telmisartan

Non-medicinal ingredients: Mannitol, sodium hydroxide, meglumine, povidone, sodium stearyl fumarate and magnesium stearate

MINT-TELMISARTAN comes in the following dosage form:

Tablets: 40 mg and 80 mg

Do not use MINT-TELMISARTAN if:

- you are allergic to telmisartan or to any non-medicinal ingredient in the formulation.
- you have experienced an allergic reaction with swelling of the face, lips, tongue, throat, or sudden difficulty breathing or swallowing to any ARB. Be sure to tell your doctor, nurse, or pharmacist that this happened to you.
- you are pregnant or intend to become pregnant. Taking MINT-TELMISARTAN during pregnancy can cause injury and even death to your baby.
- you are breastfeeding. It is possible that telmisartan passes into breast milk.
- you are allergic to some sugars (mannitol intolerant).
- you are already taking a blood pressure-lowering medicine that contains aliskiren (such as Rasilez) and you have diabetes or kidney disease.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take MINT-TELMISARTAN. Talk about any health conditions or problems you may have, including if you:

- have experienced an allergic reaction to any drug used to lower blood pressure.
- have narrowing of a heart valve, diabetes, liver or kidney disease, heart or blood vessel disease.
- are dehydrated or if you suffer from excessive vomiting, diarrhea, or sweating.
- are taking a medicine that contains aliskiren, such as Rasilez, used to lower high blood pressure. The combination with MINT-TELMISARTAN is not recommended.
- are taking an angiotensin-converting-enzyme inhibitor (ACEI).
- are taking a salt substitute that contains potassium, potassium supplements, or a potassium-sparing diuretic (a specific kind of “water pill” that makes your body keep potassium).
- are on a low salt diet.
- are on dialysis.
- are less than 18 years old.
- have been told by your doctor that you have an intolerance to some sugars.

Other warnings you should know about:

Before you perform tasks which require special attention (driving a car or operating dangerous machinery), wait until you know how you respond to MINT-TELMISARTAN. Vertigo, lightheadedness, or fainting can especially occur after the first dose and when the dose is increased.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with MINT-TELMISARTAN:

- Blood pressure lowering drugs, including diuretics (“water pills”), aliskiren-containing products (e.g. Rasilez), or angiotensin-converting-enzyme inhibitors (ACEI).
- Lithium, used to treat mood disorder.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) used to reduce pain and swelling. Examples include acetylsalicylic acid (ASA), celecoxib, naproxen and ibuprofen.
- Digoxin to treat many heart conditions.
- Warfarin, used to prevent blood clots (blood thinner).

How to take MINT-TELMISARTAN:

- Take MINT-TELMISARTAN exactly as prescribed. It is recommended to take your dose at about the same time everyday with or without food, but it should be taken the same way each day.
- Do not stop taking your medication before informing your healthcare professional.
- MINT-TELMISARTAN tablets are for once-daily oral administration and should be swallowed whole with liquid

Usual dose:

The recommended dose of MINT-TELMISARTAN is 80 mg once daily. Your doctor may prescribe 40 mg once daily if you have liver disease.

Overdose:

If you think you, or a person you are caring for, have taken too much MINT-TELMISARTAN, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you have forgotten to take your dose during the day, carry on with the next one at the usual time. Do not double dose.

What are possible side effects from using MINT-TELMISARTAN?

These are not all the possible side effects you may have when taking MINT-TELMISARTAN. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- back or leg pain, muscle cramps, joint pain, muscle spasms
- headache, anxiety
- diarrhea, constipation, nausea, vomiting, upset stomach, abdominal pain, flatulence
- dry mouth

- rash, eczema, skin eruptions
- drowsiness, insomnia, fatigue
- visual disturbances
- upper respiratory infection

MINT-TELMISARTAN can cause abnormal blood test results. Your doctor will decide when to perform blood tests and will interpret the results.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY COMMON			
Chest pain		✓	
COMMON			
Low Blood Pressure: dizziness, fainting, lightheadedness	✓		
Shortness of breath	✓		
UNCOMMON			
Depression: Low mood, loss of interest in activities, change in appetite and sleep patterns	✓		
Kidney Disorder: Change in frequency of urination, nausea, vomiting, swelling of extremities, fatigue		✓	
Increased levels of potassium in the blood: Irregular heartbeats, muscle weakness and generally feeling unwell		✓	
Urinary Tract Infections (Cystitis): Frequent or painful urination, feeling unwell		✓	
RARE			
Liver disorder: Yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite		✓	
Low blood sugar: Shaky, irregular heartbeat, sweating, hunger, dizziness (in diabetic patients)		✓	
Hyponatraemia (decreased blood sodium): nausea, vomiting,		✓	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
abdominal cramps, agitation, confusion and hallucinations			
Decreased Platelets: bruising, bleeding, fatigue and weakness		✓	
UNKNOWN			
Allergic Reaction: Rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing (potentially with fatal outcome)			✓
Sepsis (blood poisoning): Chills, confusion, fever or low body temperature, shakiness, irregular heartbeat (including fatal outcome)			✓
Rhabdomyolysis: Muscle pain that you cannot explain, muscle tenderness or weakness or dark brown urine		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

MINT-TELMISARTAN tablets should be stored at room temperature (15°C - 30°C). Due to the hygroscopic property of the tablets, they should be taken out of the sealed blister or bottles shortly before administration. Avoid excessive heat and moisture.

Keep out of reach and sight of children.

If you want more information about MINT-TELMISARTAN:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website (www.mintpharmaceuticals.com), or by calling 1-877-398-9696.

This leaflet was prepared by Mint Pharmaceuticals Inc.

Last Revised SEP 15, 2023